PLK1 and cancer: Due to its overexpression in many human tumors, Plk1 has been extensively studied as a target for anti-cancer therapy and a number of compounds that either act as ATP-competitive inhibitors or interfere with Polo-box domain functions of Plk1 have already been identified [15], [18].